Lenalidomide Teva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering the complex’s substrate specificity. This leads to degradation of transcription factors Ikaros and Aiolos, resulting in reduced cytokine production, inhibition of new blood‑vessel formation, and activation of immune cells that target malignant plasma cells.

The prescribed dose of Lenalidomide Teva is determined by the treating physician based on the specific indication, patient’s renal function, prior therapies, and overall clinical status. Dosing regimens can vary, and the prescriber will tailor the schedule to achieve optimal therapeutic benefit while monitoring safety.

Lenalidomide is classified as having unknown pregnancy category and is considered teratogenic. It should not be used during pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged while on therapy.

To request Lenalidomide Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled logistics) and the necessary import documentation.

The primary alternative to lenalidomide in many hematologic settings is thalidomide. Compared with thalidomide, lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, and provides stronger anti‑angiogenic and immunomodulatory effects. Both drugs share a common mechanism through cereblon binding, but lenalidomide is often preferred for its potency and tolerability.

Lenalidomide Teva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Lenalidomide Teva is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their healthcare provider. The exact schedule (e.g., daily or on specific days of a cycle) is set by the prescriber based on the therapeutic indication.

The most serious risks include venous thromboembolism, severe neutropenia that can lead to life‑threatening infections, and the potential development of secondary primary malignancies. Patients should be monitored closely for signs of blood clots, infections, and any new cancer diagnoses throughout treatment.

Lenalidomide Teva should not be used by individuals who are pregnant, those who cannot use effective contraception, patients with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. Clinicians must also evaluate contraindications related to concurrent therapies that pose high risk.